Search

Your search keyword '"Gordon AS"' showing total 5,434 results

Search Constraints

Start Over You searched for: Author "Gordon AS" Remove constraint Author: "Gordon AS" Journal blood Remove constraint Journal: blood
5,434 results on '"Gordon AS"'

Search Results

1. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

2. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

3. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

4. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

6. Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure

7. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

9. Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

11. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

12. Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL

13. A rapid genotyping panel for detection of primary central nervous system lymphoma

14. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

17. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

18. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

20. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

21. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism

22. PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia

23. Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition

24. Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT

25. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

26. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

28. Disruption Of PML Nuclear Bodies Cooperates In The Pathogenesis Of Acute Promyelocytic Leukemia

29. Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma

30. KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

31. Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review

35. Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

36. Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

39. Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies

40. Targetable genetic features of primary testicular and primary central nervous system lymphomas

42. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

43. Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

46. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality

48. Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

49. Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

50. Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Catalog

Books, media, physical & digital resources